Skip to main content
SpringerLink
Log in

Counteracting Estrogen as Breast Cancer Prevention

  • Chapter
Cancer Chemoprevention

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

Abstract

The association between estrogen and breast cancer growth has been appreciated for more than 100 yr, since George Beatson produced remission of advanced breast cancer by performing bilateral oophorectomy in premenopausal patients (1). Since that time, a body of evidence has accumulated supporting the hypothesis that estrogen and its metabolites are related in a complex fashion to both the initiation and promotion of breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 299.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Beatson G. On the treatment of inoperable cases of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896;2:104–107,162–165.

    Article  Google Scholar 

  2. Pfaffenberger RS Jr, Kampert JB, Chang HG. Characteristics that predict risk of breast cancer before and after the menopause. Am J Epidemiol 1980;112:258–268.

    Google Scholar 

  3. Zhang Y, Kiel DP, Kreger BE, et al. Bone mass and the risk of breast cancer among postmenopausal women. New Engl J Med 1997;336:611–617.

    Article  PubMed  CAS  Google Scholar 

  4. Magnusson C, Baron J, Persson I, et al. Body size in different periods of life and breast cancer risk in post-menopausal women. Int J Cancer 1998;76:29–34.

    Article  PubMed  CAS  Google Scholar 

  5. Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, et al. Aprospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst 1995;87:190–197.

    Article  PubMed  CAS  Google Scholar 

  6. Thomas HV, Key TJ, Allen DS, et al. A prospective study of endogenous serum hormone concentrations and breast cancer risk in post-menopausal women on the island of Guernsey. Br J Cancer 1997;76:401–405.

    PubMed  CAS  Google Scholar 

  7. The Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94(8):606–616.

    Google Scholar 

  8. Adlercreutz H, Gorbach SL, Goldin BR, et al. Estrogen metabolism and excretion in Oriental and Caucasian women. J Natl Cancer Inst 1994;86:1076–1082.

    Article  PubMed  CAS  Google Scholar 

  9. Schairer C, Lubin J, Troisi R, et al. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000;283:485–491.

    Article  PubMed  CAS  Google Scholar 

  10. Persson I, Weiderpass E, Bergkvist L, et al. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Control 1999;10:253–260.

    Article  PubMed  CAS  Google Scholar 

  11. Gapstur SM, Morrow M, Sellers TA. Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women’s Health Study. JAMA 1999;281:2091–2097.

    Article  PubMed  CAS  Google Scholar 

  12. Brinton LA, Brogan DR, Coates RJ, et al. Breast cancer risk among women under 55 years of age by joint effects of usage of oral contraceptives and hormone replacement therapy. Menopause 1998;5:145–151.

    PubMed  CAS  Google Scholar 

  13. Titus-Ernstoff L, Longnecker MP, Newcomb PA, et al. Menstrual factors in relation to breast cancer risk. Cancer Epidemiol Biomarkers Prev 1998;7:783–789.

    PubMed  CAS  Google Scholar 

  14. Henrich JB, Kornguth PJ, Viscoli CM, Horwitz RI. Postmenopausal estrogen use and invasive versus in situ breast cancer risk. J Clin Epidemiol 1998;51:1277–1283.

    Article  PubMed  CAS  Google Scholar 

  15. Magnusson C, Baron JA, Correia N, et al. Breast-cancer risk following long-term oestrogen-and oestrogen-progestin-replacement therapy. Int J Cancer 1999;81:339–344.

    Article  PubMed  CAS  Google Scholar 

  16. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. 1999: Hormonal Contraception and Postmenopausal Hormone Therapy 1999;72:474–530.

    Google Scholar 

  17. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321–333.

    Article  Google Scholar 

  18. Colditz GA. Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J Natl Cancer Inst 1998;90:814–823.

    Article  PubMed  CAS  Google Scholar 

  19. Rohan TE, Miller AB. A cohort study of oral contraceptive use and risk of benign breast disease. Int J Cancer 1999;82:191–196.

    Article  PubMed  CAS  Google Scholar 

  20. Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med 2002;346:2025–2032.

    Article  PubMed  CAS  Google Scholar 

  21. Kristensen VN, Andersen TI, Lindblom A, et al. A rare CYP19 (aromatase) variant may increase the risk of breast cancer. Pharmacogenetics 1998;8:43–48.

    Article  PubMed  CAS  Google Scholar 

  22. Siegelmann-Danieli N, Buetow KH. Constitutional genetic variation at the human aromatase gene (Cyp19) and breast cancer risk. Br J Cancer 1999;79:456–463.

    Article  PubMed  CAS  Google Scholar 

  23. Taioli E, Trachman J, Chen X, et al. A CYP1A1 restriction fragment length polymorphism is associated with breast cancer in African-American women. Cancer Res 1995;55: 3757–3758.

    PubMed  CAS  Google Scholar 

  24. Ishibe N, Hankinson SE, Colditz GA, et al. Cigarette smoking, cytochrome P450 1A1 polymorphisms, and breast cancer risk in the Nurses’ Health Study. Cancer Res 1998;58:667–671.

    PubMed  CAS  Google Scholar 

  25. Feigelson HS, Coetzee GA, Kolonel LN, et al. A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res 1997;57:1063–1065.

    PubMed  CAS  Google Scholar 

  26. Lavigne JA, Helzlsouer KJ, Huang HY, et al. An association between the allele coding for a low activity variant of catechol-O-methyltransferase and the risk for breast cancer. Cancer Res 1997;57:5493–5497.

    PubMed  CAS  Google Scholar 

  27. Thompson PA, Shields PG, Freudenheim JL, et al. Genetic polymorphisms in catechol-O-methyltransferase, menopausal status, and breast cancer risk. Cancer Res 1998;58:2107–2110.

    PubMed  CAS  Google Scholar 

  28. Harvell DM, Strecker TE, Tochacek M, et al. Rat strainspecific actions of 17beta-estradiol in the mammary gland: correlation between estrogen-induced lobuloalveolar hyperplasia and susceptibility to estrogen-induced mammary cancers. Proc Natl Acad Sci USA 2000;97:2779–2784.

    Article  PubMed  CAS  Google Scholar 

  29. Liehr JG, Fang WF, Sirbasku DA, Ari-Ulubelen A. Carcinogenicity of catechol estrogens in Syrian hamsters. J Steroid Biochem 1986;24:353–356.

    Article  PubMed  CAS  Google Scholar 

  30. Kirkman H. Hormone-related tumors in Syrian hamsters. Prog Exp Tumor Res 1972;16:201–240.

    PubMed  CAS  Google Scholar 

  31. Li JJ, Li SA. Estrogen carcinogenesis in hamster tissues: role of metabolism. Fed Proc 1987;46: 1858–1863.

    PubMed  CAS  Google Scholar 

  32. Kirkman H. Estrogen-induced tumors of the kidney. III. Growth characteristics in the Syrian hamster. Natl Cancer Inst Monogr 1959;1:1–57.

    PubMed  CAS  Google Scholar 

  33. Newbold RR, Liehr JG. Induction of uterine adenocarcinoma in CD-1 mice by catechol estrogens. Cancer Res 2000;60:235–237.

    PubMed  CAS  Google Scholar 

  34. Newbold RR, Bullock BC, McLachlan JA. Uterine adenocarcinoma in mice following developmental treatment with estrogens: a model for hormonal carcinogenesis. Cancer Res 1990;50:7677–7681.

    PubMed  CAS  Google Scholar 

  35. Liehr JG, Gladek A, Macatee T, et al. DNA adduct formation in liver and kidney of male Syrian hamsters treated with estrogen and/or α-naphthoflavone. Carcinogenesis 1991;21:385–389.

    Article  Google Scholar 

  36. Liehr JG, Wheeler WJ. Inhibition of estrogen-induced renal carcinoma in Syrian hamsters by vitamin C. Cancer Res 1983;43:4638–4642.

    PubMed  CAS  Google Scholar 

  37. National Institutes of Environmental Health Toxicology Program. Tenth Report on Carcinogens. Dept. of Health and Human Services, Washington DC, 2002.

    Google Scholar 

  38. Feigelson HS, Henderson BE. Estrogens and breast cancer. Carcinogenesis 1996;17:2279–2284.

    Article  PubMed  CAS  Google Scholar 

  39. Clarke RB, Howell A, Potten CS, Anderson E. Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 1997;57(22):4987–4991.

    PubMed  CAS  Google Scholar 

  40. Russo J, Ao X, Grill C, Russo IH. Pattern of distribution of cells positive for estrogen receptor alpha and progesterone receptor in relation to proliferating cells in the mammary gland. Breast Cancer Res Treat 1999; 53:217–227.

    Article  PubMed  CAS  Google Scholar 

  41. Bocchinfuso WP, Hively WP, Couse JF, et al. A mouse mammary tumor virus-Wnt-1 transgene induces mammary gland hyperplasia and tumorigenesis in mice lacking estrogen receptor-alpha. Cancer Res 1999;59:1869–1876.

    PubMed  CAS  Google Scholar 

  42. Cavalieri EL, Stack DE, Devanesan PD, et al. Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators. Proc Natl Acad Sci USA 1997;94: 10,937–10,942.

    Article  PubMed  CAS  Google Scholar 

  43. Wang MY, Liehr JG. Induction by estrogens of lipid peroxidation and lipid peroxide-derived malonaldehyde-DNA adducts in male Syrian hamsters: role of lipid peroxidation in estrogen-induced kidney carcinogenesis. Carcinogenesis 1995;16:1941–1945.

    Article  PubMed  CAS  Google Scholar 

  44. Banerjee SK, Banerjee S, Li SA, Li JJ. Induction of chromosome aberrations in Syrian hamster renal cortical cells by various estrogens. Mutat Res 1994;311:191–197.

    PubMed  CAS  Google Scholar 

  45. Li JJ, Gonzalez A, Banerjee S, et al. Estrogen carcinogenesis in the hamster kidney: role of cytotoxicity and cell proliferation. Environ Health Perspect 1993;101(suppl 5):259–264.

    Article  PubMed  CAS  Google Scholar 

  46. Tsutsui T, Barret JC. Neoplastic transformation of cultured mammalian cells by estrogens and estrogenlike chemicals. Environ Health Perspect 1997;105:619–624.

    Article  PubMed  CAS  Google Scholar 

  47. Tsutsui T, Tamura Y, Hagiwara M, et al. Induction of mammalian cell transformation and genotoxicity by 2-methoxyestradiol, an endogenous metabolite of estrogen. Carcinogenesis 2000;21:735–740.

    Article  PubMed  CAS  Google Scholar 

  48. Li JJ, Hou X, Banerjee SK, et al. Overexpression and amplification of c-myc in the Syrian hamster kidney during estrogen carcinogenesis: a probable critical role in neoplastic transformation. Cancer Res 1999;59:2340–2346.

    PubMed  CAS  Google Scholar 

  49. Russo J, Lareef MH, Tahin Q, et al. 17-β-estradiol is carcinogenic in human breast epithelial cells. J Steroid Biochem Mol Biol 2002;1656:1–17.

    Google Scholar 

  50. Kong LY, Szaniszlo P, Albrecht T, Liehr JG. Frequency and molecular analysis of hprt mutations induced by estradiol in Chinese hamster V79 cells. Int J Oncol 2000;17:1141–1149.

    PubMed  CAS  Google Scholar 

  51. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998;396:643–649.

    Article  PubMed  CAS  Google Scholar 

  52. Bulun SE, Price TM, Mahendroo MS, et al. A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription. J Clin Endocrinol Metab 1993;77:1622–1628.

    Article  PubMed  CAS  Google Scholar 

  53. Harada N. Aberrant expression of aromatase in breast cancer tissues. J Steroid Biochem Mol Biol 1997;61:175–184.

    Article  PubMed  CAS  Google Scholar 

  54. James VHT, McNeill JM, Lai LC, et al. Aromatase activity in normal breast and breast tumor tissues: in vivo and in vitro studies. Steroids 1987;50:269–279.

    Article  PubMed  CAS  Google Scholar 

  55. Miller WR, O’Neill J. The importance of local synthesis of estrogen within the breast. Steroids 1987;50:537–548.

    Article  PubMed  CAS  Google Scholar 

  56. Miller WR, Mullen P, Sourdaine P, et al. Regulation of aromatase activity within the breast. J Steroid Biochem Mol Biol 1997;61:193–202.

    PubMed  Google Scholar 

  57. Brodie A, Lu Q, Liu Y, Long B. Aromatase inhibitors and their antitumor effects in model systems. Endocr Relat Cancer 1999;6:205–210.

    Article  PubMed  CAS  Google Scholar 

  58. Tekmal RR, Ramachandra N, Gubba S, et al. Overexpression of int-5/aromatase in mammary glands of transgenic mice results in the induction of hyperplasia and nuclear abnormalities. Cancer Res 1996;56: 3180–3185.

    PubMed  CAS  Google Scholar 

  59. Tekmal RR, Kirma N, Gill K, et al. Aromatase overexpression and breast hyperplasia, an in vivo model-continued overexpression of aromatase is sufficient to maintain hyperplasia without circulating estrogens, and aromatase inhibitors abrogate these preneoplastic changes in mammary glands. Endocr Relat Cancer 1999;6:307–314.

    Article  PubMed  CAS  Google Scholar 

  60. Santner SJ, Pauley RJ, Tait L, et al. Aromatase activity and expression in breast cancer and benign breast tissue stromal cells. J Clin Endocrinol Metab 1997;82:200–208.

    Article  PubMed  CAS  Google Scholar 

  61. Jin T, Zhang X, Li H, Goss PE. Characterization of a novel silencer element in the human aromatase gene PII promoter. Breast Cancer Res Treat 2000;62:151–159.

    Article  PubMed  CAS  Google Scholar 

  62. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989; 320:479–484.

    PubMed  CAS  Google Scholar 

  63. Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh. Adjuvant tamoxifen in the management of operable breast cancer: The Scottish Trial. Lancet 1987;2:171–175.

    Google Scholar 

  64. Early Breast Cancer Trialists’ Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31000 recurrences and 24000 deaths among 75000 women. Lancet 1992;339:1–15, 71–78.

    Google Scholar 

  65. Fisher B, Costantino J, Wickerham L, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1. J Natl Cancer Inst 1998;90:1371–1388.

    Article  PubMed  CAS  Google Scholar 

  66. Cuzick J. The prevention of breast cancer. Program and abstracts of the 3rd European Breast Cancer Conference, March 19–23, 2002; Barcelona, Spain.

    Google Scholar 

  67. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 1998; 352:93–97.

    PubMed  CAS  Google Scholar 

  68. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998;352:98–101.

    PubMed  CAS  Google Scholar 

  69. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999;353:1993–2000.

    Article  PubMed  CAS  Google Scholar 

  70. Cummings R, Eckert S, Krueger K, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women. Results from the MORE randomized trial. JAMA 1999;281:2189–2197.

    Article  PubMed  CAS  Google Scholar 

  71. Jordan VC, Glusman, JE, Eckert S, et al. Raloxifene reduces incident primary breast cancer: integrated data from multicenter, double-blind, placebo-controlled, randomized trials in postmenopausal women. Breast Cancer Res Treat 1998;50:227 (abstr 2).

    Google Scholar 

  72. Cummings SR, Duong T, Kenyon E, et al. Serum estradiol level and risk of breast cancer during treatment with raloxifene. The Multiple Outcomes of Raloxifene Evaluation (MORE) Trial. JAMA 2002;287:1528.

    Article  Google Scholar 

  73. Pink JJ, Jordan VC. Models of estrogen receptor regulation by estrogen and antiestrogens in breast cancer ell lines. Cancer Res 1996;56:2321–2330.

    PubMed  CAS  Google Scholar 

  74. Parker MG. Action of “pure” antiestrogens in inhibiting estrogen receptor action. Breast Cancer Res Treat 1993;26:131–137.

    Article  PubMed  CAS  Google Scholar 

  75. Dauvois S, White R, Parker MG. The antiestrogens ICI 182,780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 1993;106:1377–1388.

    PubMed  CAS  Google Scholar 

  76. Coopman P, Garcia M, Brunner N, et al. Anti-proliferative and anti-estrogenic effects of ICI 164,384 and ICI 182,780 in 4-OH-tamoxifen resistant human breast cancer cells. Int J Cancer 1994;56:295–300.

    Article  PubMed  CAS  Google Scholar 

  77. Hu XF, Veroni M, de Luise M, et al. Circumvention of tamoxifen resistance by the pure anti-estrogen ICI 182,780. Int J Cancer 1993;55:873–876.

    Article  PubMed  CAS  Google Scholar 

  78. Osborne CK, Pippen J, Jones SE, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002;20:3386–3395.

    Article  PubMed  CAS  Google Scholar 

  79. Howell A, Robertson JF, Quaresma Albano J, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002;20:3396–3403.

    Article  PubMed  CAS  Google Scholar 

  80. Howell A, Robertson JFR, Albano JQ, et al. Comparison of efficacy and tolerability of Faslodex (ICI 182,780) with Arimidex (anastrozole) in postmenopausal women with advanced breast cancer—preliminary results. Breast Cancer Res Treat 2000;64:27 (abstr 6).

    Google Scholar 

  81. Gutman M, Couillard S, Roy J, et al. Comparison of the effects of EM-652 (SCH57068), tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and raloxifene on the growth of human ZR-75-1 breast tumors in nude mice. Int J Cancer 2002;99:273–278.

    Article  PubMed  CAS  Google Scholar 

  82. Martel C, Picard S, Richard V, et al. Prevention of bone loss by EM-800 and raloxifene in the ovariectomized rat. J Steroid Biochem Mol Biol 2000;74:45–56.

    Article  PubMed  CAS  Google Scholar 

  83. Labrie F, Labrie C, Belanger A, et al. EM-652 (SCH57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometrium. Steroid Biochem Mol Biol 2001;79:213–225.

    Article  CAS  Google Scholar 

  84. Cohen LA, Pittman B, Wang, CX, et al. LAS, a novel selective estrogen receptor modulator with chemopreventive and therapeutic activity in the N-nitroso-N-methylurea-induced rat mammary tumor model. Cancer Res 2001; 61:8683–8688.

    PubMed  CAS  Google Scholar 

  85. Suh N, Glasebrook AL, Palkowitz AD, et al. Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer. Cancer Res 2001;61:8412–8415.

    PubMed  CAS  Google Scholar 

  86. Shibata J, Toko T, Saito H, et al. Estrogen agonistic/antagonistic effects of miproxifene phosphate (TAT-59). Cancer Chemother Pharmacol 2000;45:133–141.

    Article  PubMed  CAS  Google Scholar 

  87. Noguchi S, Koyama H, Nomura Y, et al. Late Phase II study of TAT-59 (new antiestrogen) in advanced or recurrent breast cancer patient: a double-blind comparative study with tamoxifen citrate. Breast Cancer Res Treat 1998; 50:307 (abstr 446).

    Google Scholar 

  88. Buzdar A, Hyes D, El-Khoudary A, et al. Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced beast cancer. Breast Cancer Res Treat 2002;73: 161–175.

    Article  PubMed  CAS  Google Scholar 

  89. Brzezinski A, Debi A. Phytoestrogens: the “natural” selective estrogen receptor modulators? Eur J Obstet Gynecol Reprod Biol 1999;85:47–51.

    Article  PubMed  CAS  Google Scholar 

  90. Serraino M, Thompson LU. The effect of flaxseed supplementation on the initiation and promotional stages of mammary tumorigenesis. Nutr Cancer 1992;17:153–159.

    PubMed  CAS  Google Scholar 

  91. Hirano T, Fukuoka K, Oka K, et al. Antiproliferative activity of mammalian lignan derivatives against the human breast carcinoma cell line, ZR-75-1. Cancer Invest 1990;8:595–602.

    Article  PubMed  CAS  Google Scholar 

  92. Thompson LU, Rickard SE, Orcheson LJ, Seidl MM. Flaxseed and its lignan and oil components reduce mammary tumor growth at a late stage of carcinogenesis. Carcinogenesis 1996;17:1373–1376.

    Article  PubMed  CAS  Google Scholar 

  93. Haggans CJ, Hutchins AM, Olson BA, et al. Effect of flaxseed consumption on urinary estrogen metabolites in postmenopausal women. Nutr Cancer 1999;33:188–195.

    Article  PubMed  CAS  Google Scholar 

  94. Phipps WR, Martini MC, Lampe JW, et al. Effect of flax seed ingestion on the menstrual cycle. J Clin Endocrinol Metab 1993;77:1215–1219.

    Article  PubMed  CAS  Google Scholar 

  95. Hutchins AM, Martini MC, Olson BA, et al. Flaxseed consumption influences endogenous hormone concentrations in post-menopausal women. Nutr Cancer 2001;39:58–65.

    Article  PubMed  CAS  Google Scholar 

  96. Goss PE, Li T, Theriault M, et al. Effects of dietary flaxseed in women with cyclical mastalgia. Breast Cancer Res Treat 2000;64:49 (abstr 153).

    Article  Google Scholar 

  97. Goss PE, Thompson LU. The effects of dietary flaxseed on mammographic density. Breast Cancer Res Treat 2001;69: 223 (abstr 125).

    Google Scholar 

  98. Thompson L, Li T, Chen J, Goss PE. Biological effects of dietary flaxseed in patients with breast cancer. Breast Cancer Res Treat 2000;64:50 (abstr 157).

    Google Scholar 

  99. Lamartiniere CA, Moore JB, Brown NM, et al. Genistein suppresses mammary cancer in rats. Carcinogenesis 1995;16:2833–2840.

    Article  PubMed  CAS  Google Scholar 

  100. Hawrylewicz EJ, Zapata JJ, Blair WH. Soy and experimental cancer: animal studies. J Nutr 1995; 125(Suppl 3): 698–708.

    Google Scholar 

  101. Gallo D, Giacomelli S, Cantelmo F, et al. Chemoprevention of DMBA-induced mammary cancer in rats by dietary soy. Breast Cancer Res Treat 2001;69:153–164.

    Article  PubMed  CAS  Google Scholar 

  102. Ju YH, Allred CD, Allred KF, et al. Physiological concentrations of dietary genistein dose-dependently stimulate growth of estrogen-dependent human breast cancer (MCF-7) tumors implanted in athymic nude mice. J Nutr 2001;131:2957–2962.

    PubMed  CAS  Google Scholar 

  103. Allred CD, Ju YH, Allred KF, et al. Dietary genistein stimulates growth of estrogen-dependent breast cancer tumors similar to that observed with genistein. Carcinogenesis 2001;22:1667–1673.

    Article  PubMed  CAS  Google Scholar 

  104. Allred CD, Allred KF, Ju YH, et al. Soy diets containing varying amounts of genistein stimulate growth of estrogendependent (MCF-7) tumors in a dose-dependent manner. Cancer Res 2001;61:5045–5050.

    PubMed  CAS  Google Scholar 

  105. de Lemos ML. Effects of soy phytoestrogens genistein and daidzein on breast cancer growth. Ann Pharmacother 2001;35:1118–1121.

    Article  PubMed  Google Scholar 

  106. Jones JL, Daley BJ, Enderson BL, et al. Genistein inhibits tamoxifen effects on cell proliferation and cell cycle arrest in T47D breast cancer cells. Am Surg 2002;68:575–577.

    PubMed  Google Scholar 

  107. Ju YH, Doerge DR, Allred KF, et al. Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice. Cancer Res 2002;62: 2474–2477.

    PubMed  CAS  Google Scholar 

  108. Lamartiniere CA, Cotroneo MS, Fritz WA, et al. Genistein chemoprevention: timing and mechanisms of action in murine mammary and prostate. J Nutr 2002;132:552S–558S.

    PubMed  Google Scholar 

  109. Kumar NB, Cantor A, Allen K, et al. The specific role of isoflavones on estrogen metabolism in premenopausal women. Cancer 2002;94:1166–1174.

    Article  PubMed  CAS  Google Scholar 

  110. Shu XO, Jin F, Dai Q. Soyfood intake during adolescence and subsequent risk of breast cancer among Chinese women. Cancer Epidemiol Biomarkers Prev 2001;10:483–488.

    PubMed  CAS  Google Scholar 

  111. Shanghai Dai Q, Shu XO, Jin F. Population-based case-control study of soyfood intake and breast cancer risk. Br J Cancer 2001;85:372–378.

    Article  Google Scholar 

  112. Horn-Ross PL, John EM, Lee M. Phytoestrogen consumption and breast cancer risk in a multiethnic population: the Bay Area Breast Cancer Study. Am J Epidemiol 2001; 154: 434–441.

    Article  PubMed  CAS  Google Scholar 

  113. Goss PE, Strasser K. Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol 2001;19: 881–894.

    PubMed  CAS  Google Scholar 

  114. Nabholtz JM, Buzdar A, Pollak M. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000;18:3758–3767.

    PubMed  CAS  Google Scholar 

  115. Bonneterre J, Buzdar A, Nabholtz JM, et al. Arimidex Writing Committee. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Investigators Committee Members. Cancer 2001;92:2247–2258.

    Article  PubMed  CAS  Google Scholar 

  116. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a Phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001;19:2596–2606.

    PubMed  CAS  Google Scholar 

  117. Dirix L, Piccart MJ, Lohrisch C, et al. Efficacy of and tolerance to exemestane (E) versus tamoxifen (T) in 1st line hormone therapy (HT) of postmenopausal metastatic breast cancer (MBC) patients (pts): a European Organisation for the Research and Treatment of Cancer (EORTC Breast Group) Phase II trial with Pharmacia and Upjohn. Proc Am Soc Clin Oncol 2001;20:29a (abstr 114).

    Google Scholar 

  118. Miller WR, Dixon JM. Local endocrine effects of aromatase inhibitors within the breast. J Steroid Biochem Mol Biol 2001;79:93–102.

    Article  PubMed  CAS  Google Scholar 

  119. The ATAC Trialists’ Group. Arimidex, tamoxifen alone or in combination. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131–2139.

    Article  Google Scholar 

  120. Gunson DE, Steele RE, Chau RY. Prevention of spontaneous tumours in female rats by fadrozole hydrochloride, an aromatase inhibitor. Br J Cancer 1995;72:72–75.

    PubMed  CAS  Google Scholar 

  121. Moon RC, Steele VE, Kelloff GJ, et al. Chemoprevention of MNU-induced mammary tumorigenesis by hormone response modifiers: toremifene, RU 16117, tamoxifen, aminoglutethimide and progesterone. Anticancer Res 1994;14: 889–894.

    PubMed  CAS  Google Scholar 

  122. De Coster R, Van Ginckerl RF, Callens MJ, et al. Antitumoral and endocrine effects of (+)-vorozole in rats bearing dimethylbenzanthracene-induced mammary tumors. Cancer Res 1992;52:1240–1244.

    PubMed  Google Scholar 

  123. Lubet RA, Steele VE, Casebolt TL, et al. Chemopreventive effects of the aromatase inhibitors vorozole (R-83842) and 4-hydroxyandrostenedione in the methylnitrosourea (MNU)-induced mammary tumor model in Sprague-Dawley rats. Carcinogenesis 1994;15:2775–2780.

    Article  PubMed  CAS  Google Scholar 

  124. Schieweck K, Bhatnagar AS, Matter A. CGS 16949A, a new nonsteroidal aromatase inhibitor: effects on hormonedependent and-independent tumors in vivo. Cancer Res 1988;48:834–838.

    PubMed  CAS  Google Scholar 

  125. Schieweck K, Bhatnagar AS, Batzl C, et al. Anti-tumor and endocrine effects of non-steroidal aromatase inhibitors on estrogen-dependent rat mammary tumors. J Steroid Biochem Mol Biol 1993;44:633–636.

    Article  PubMed  CAS  Google Scholar 

  126. Bhatnagar AS, Hausler A, Schieweck K, et al. Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor. J Steroid Biochem Mol Biol 1990;37:1021–1027.

    Article  PubMed  CAS  Google Scholar 

  127. Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451–1467.

    Article  Google Scholar 

  128. Chlebowski RT, Collyar DE, Somerfield MR, et al. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene. J Clin Oncol 1999;17:1939–1955.

    PubMed  CAS  Google Scholar 

  129. McDonald CC, Alexander FE, Whyte BW, et al. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial: the Scottish Cancer Trials Breast Group. Br Med J 1995; 311:977–980.

    CAS  Google Scholar 

  130. McDonald CC, Stewart HJ. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial: The Scottish Breast Cancer Committee. Br Med J 1991;303:435–437.

    CAS  Google Scholar 

  131. Costantino JP, Kuller LH, Ives DG, et al. Coronary heart disease mortality and adjuvant tamoxifen therapy. J Natl Cancer Inst 1997;89:776–782.

    Article  PubMed  CAS  Google Scholar 

  132. Ruqvist LE, Matteson A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen: The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 1993;85:1398–1406.

    Article  Google Scholar 

  133. Love RR, Barden HS, Mazess RB, et al. Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Intern Med 1994;154:2585–2588.

    Article  PubMed  CAS  Google Scholar 

  134. Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992;326:852–856.

    PubMed  CAS  Google Scholar 

  135. Love RR, Mazess RB, Torney DC, et al. Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two years. Breast Cancer Res Treat 1998;12:297–302.

    Article  Google Scholar 

  136. Chittacharoen A, Theppisai U, Manonai J. Transvaginal color Doppler sonographic evaluation of the uterus in postmenopausal women on daily raloxifene therapy. Climacteric 2002;5:156–159.

    Article  PubMed  CAS  Google Scholar 

  137. Delmas PD, Bjamasan NG, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641–1647.

    Article  PubMed  CAS  Google Scholar 

  138. Boss SM, Huster WJ, Neild JA, et al. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am J Obstet Gynecol 1997;177:1458–1464.

    Article  PubMed  CAS  Google Scholar 

  139. Draper MW, Flowers DE, Huster WJ, et al. A controlled trial of raloxifene (LY13948I) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Mineral Res 1996;11: 835–842.

    Article  CAS  Google Scholar 

  140. Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998;279:1445–1485.

    Article  PubMed  CAS  Google Scholar 

  141. Mosca L. Rationale and overview of the Raloxifene Use for the Heart (RUTH) trial. Ann NY Acad Sci 2001;949:181–185.

    PubMed  CAS  Google Scholar 

  142. Glusman JE, Huster WJ, Paul S. Raloxifene effects on vasomotor and other climacteric symptoms in postmenopausal women. Prim Care Update Ob Gyns 1998;5:166.

    Article  PubMed  Google Scholar 

  143. Picard F, Deshaies Y, Lalonde J, et al. Effects of the estrogen antagonist EM-652.HCl on energy balance and lipid metabolism in ovariectomized rats. Int J Obes Relat Metab Disord 2000;24:830–840.

    Article  PubMed  CAS  Google Scholar 

  144. Dardes RC, Bentrem D, O’Regan RM, et al. Effects of the new selective estrogen receptor modulator LY353381.HCl (Arzoxifene) on human endometrial cancer growth in athymic mice. Clin Cancer Res 2001;7: 4149–4155.

    PubMed  CAS  Google Scholar 

  145. Galbiati E, Caruso PL, Amari G, et al. Effects of 3-phenyl-4-[[4-[2-(1-piperidinyl)ethoy]phenyl]methyl]-2H-1-benzopyran-7-ol (CHF4056), a novel nonsteroidal estrogen agonist/antagonist, on reproductive and nonreproductive tissue. J Pharmacol Exp Ther 2002;300:802–809.

    Article  PubMed  CAS  Google Scholar 

  146. Greenberger LM, Annable T, Collins I, et al. A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-ylethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and-resistant tumors and is devoid of uterotrophic effects in mice and rats. Clin Cancer Res 2001;7:3166–3177.

    PubMed  CAS  Google Scholar 

  147. Dewar J, Nabholtz J-MA, Monneterre J, et al. The effect of anastrozole (Arimidex™) on serum lipids—data from a randomized comparison of anastrozole (AN) vs tamoxifen (TAM) in postmenopausal (PM) women with advanced breast cancer (ABC). Breast Cancer Res Treat 2000;64:51 (abstr 164).

    Google Scholar 

  148. Heshmati HM, Khosla S, Robins SP, et al. Endogenous residual estrogen levels determine bone resorption even in late postmenopausal women. J Bone Mineral Res 1997;12:S121 (abstr 76).

    Google Scholar 

  149. Harper-Wynne C, Ross G, Sacks N, Dowsett M. A pilot prevention study of the aromatase inhibitor letrozole: effects on breast cell proliferation and bone/lipid indices in healthy postmenopausal women. Breast Cancer Res Treat 2001;69: 225 (abstr 136).

    Google Scholar 

  150. Harper-Wynne C, Ross G, Sacks N, et al. Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention. Cancer Epidemiol Biomarkers Prev 2002;11:614–621.

    PubMed  CAS  Google Scholar 

  151. Elisaf MS, Bairaktari ET, Nicolaides C, et al. Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. Eur J Cancer 2001;37:1510–1513.

    Article  PubMed  CAS  Google Scholar 

  152. Goss PE, Grynpas M, Qi S, Hu H. The effects of exemestane on bone and lipids in the ovariectomized rat. Breast Cancer Res Treat, 2001; 69:224 (abstr 132).

    Google Scholar 

  153. Lohrisch C, Paridaens R, Dirix LY. No adverse impact on serum lipids of the irreversible aromatase inactivator Aromasin® (exemestane [E]) in 1st line treatment of metastatic breast cancer (MBC): companion study to a European Organization of Research and Treatment of Cancer (Breast Group) Trial with Pharmacias’ Upjohn. Proc Am Soc Clin Oncol 2001;20:43a (abstr 167).

    Google Scholar 

  154. Day R, Ganz PA, Costatino JP, et al. Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol 1999;17: 2659–2669.

    PubMed  CAS  Google Scholar 

  155. Fallowfield L and ATAC Trialists’ Group. Assessing the quality of life (QOL) of postmenopausal (PM) women randomized into the ATAC (“Arimidex”, tamoxifen, alone or in combination) adjuvant breast cancer (BC) trial. Proc Am Soc Clin Oncol 2002;21:40a (abstr 159).

    Google Scholar 

  156. Paridaens R, Dirix L, Beex L, et al. Promising results with exemestane in the first-line treatment of metastatic breast cancer: a randomized phase II EORTC trial with a tamoxifen control. Clin Breast Cancer 2000; 1(Suppl 1):S19–S21.

    Article  PubMed  Google Scholar 

  157. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879–1886.

    Article  PubMed  CAS  Google Scholar 

  158. Chlebowski RT, Col N, Winer EP. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibitors. J Clin Oncol 2002;20:3328–3343.

    Article  PubMed  CAS  Google Scholar 

  159. Goss PE, Sierra S. Current perspectives on radiation-induced breast cancer. J Clin Oncol 1998; 16:338–347.

    PubMed  CAS  Google Scholar 

  160. Arun B, Zhang H, Mirza NQ, et al. Growth inhibition of breast cancer cells by celecoxib. Breast Cancer Res Treat 2001;69:234 (abstr 171).

    Google Scholar 

  161. Pesenti E, Masferrer JL, di Salle E. Effect of exemestane and celecoxib alone or in combination on DMBA-induced mammary carcinoma in rats. Breast Cancer Res Treat 2001;69: 288 (abstr 445).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. First Medical Department with Medical Oncology, Wilhelminen Hospital, Vienna, Austria

    Kathrin Strasser-Weippl MD

  2. Princess Margaret Hospital, University Health Network, Toronto, Canada

    Paul E. Goss MD, PhD, FRCPC, FRCP (UK)

Authors
  1. Kathrin Strasser-Weippl MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul E. Goss MD, PhD, FRCPC, FRCP (UK)
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Biomedical Imaging Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD

    Gary J. Kelloff MD

  2. Gastrointestinal and Other Cancers Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD

    Ernest T. Hawk MD, MPH

  3. CCS Associates, Mountain View, CA

    Caroline C. Sigman PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Strasser-Weippl, K., Goss, P.E. (2005). Counteracting Estrogen as Breast Cancer Prevention. In: Kelloff, G.J., Hawk, E.T., Sigman, C.C. (eds) Cancer Chemoprevention. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1007/978-1-59259-768-0_19

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-768-0_19

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-077-9

  • Online ISBN: 978-1-59259-768-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation